Cancer Research includes companies working on scientific research aimed at understanding the causes, prevention, diagnosis, treatment, and potential cures for cancer. It includes many disciplines, from biology and genetics, to clinical trials and drug development, with the ultimate goal of improving cancer care and outcomes. Cancer research companies are developing life-saving treatments and diagnostics for a growing market in high demand. These companies constantly innovate, have a global reach, and form important strategic partnerships, which makes them appealing to investors looking for profits and supporting health progress.
Bristol-Myers Squibb Analyst Ratings
TD Cowen Adjusts Price Target on Bristol-Myers Squibb to $53 From $45, Maintains Hold Rating
Analysts' Top Healthcare Picks: Generation Bio (GBIO), Bristol-Myers Squibb (BMY)
Analysts Offer Insights on Healthcare Companies: Enanta Pharmaceuticals (ENTA), Hyperfine (HYPR) and Biogen (BIIB)
Gilead Sciences: A Cautious Hold Amidst Mixed Performance and Future Uncertainties
RBC Capital Maintains Sector Perform on Gilead Sciences, Raises Price Target to $72
Deutsche Bank Keeps Their Hold Rating on Gilead Sciences (GILD)
Gilead Sciences (GILD) Gets a Hold From Cantor Fitzgerald
Gilead Sciences: Hold Rating Affirmed Amid Mixed Performance and Cautious Outlook
Gilead Sciences Analyst Ratings
Morgan Stanley Raises Price Target on Gilead Sciences to $79 From $74, Keeps Equalweight Rating
Gilead Sciences Poised for Growth: A Strong Buy Rating With a $93 Price Target
Pfizer Analyst Ratings
Deutsche Bank Adjusts Price Target on Merck to $145 From $140
Daiwa Securities Upgrades Pfizer to Outperform From Neutral, Adjusts Price Target to $34 From $28
Analysts' Opinions Are Mixed on These Healthcare Stocks: Blueprint Medicines (BPMC), Adaptimmune Therapeutics (ADAP) and Ardelyx (ARDX)
Mizuho Securities Maintains Biogen(BIIB.US) With Buy Rating, Cuts Target Price to $251
Daiwa Securities Adjusts Merck & Company Price Target to $130 From $150, Maintains Outperform Rating
Truist Financial Maintains Pfizer(PFE.US) With Buy Rating
Biogen Analyst Ratings